Blindness

Spark Therapeutics Inc (NASDAQ: ONCE), a gene therapy company that treats orphan diseases including a rare retinal disease that can lead to blindness, said in early January it will price its therapy at $850,000 for a one-time treatment of both eyes. The Analyst Wedbush's David Nierengarten...

Shares of Second Sight Medical Products Inc (NASDAQ: EYES) surged higher by 15 percent on Monday and traded above the $5 per share mark for the first time since early January. Second Sight is a medical device company that develops implantable visual prosthetics to restore some functional vision to...

Shares of Spark Therapeutics Inc (NASDAQ: ONCE) opened higher by more than 40 percent on Monday. Spark's product candidate, SPK-RPE65, targets a group of rare blinding conditions known as inherited retinal dystrophies. Spark announced on Monday its SPK-RPE65 met the goals of a late-stage study....